Connor, Clark & Lunn Investment Management Ltd. Ultragenyx Pharmaceutical Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 5,885 shares of RARE stock, worth $202,444. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,885

Previous 44,901 86.89%

Holding current value

$202,444

Previous $1.63 Million 86.89%

% of portfolio

0.0%

Previous 0.01%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$31.06 - $39.3 $1.21 Million - $1.53 Million	-39,016 Reduced 86.89%	5,885 $213,000
Q1 2025 May 12, 2025	BUY	$36.21 - $45.78 $647,615 - $818,775	17,885 Added 66.2%	44,901 $1.63 Million
Q4 2024 Feb 10, 2025	SELL	$42.07 - $57.72 $2.03 Million - $2.78 Million	-48,249 Reduced 64.11%	27,016 $1.14 Million
Q3 2024 Nov 08, 2024	SELL	$40.21 - $59.36 $3.52 Million - $5.2 Million	-87,626 Reduced 53.79%	75,265 $4.18 Million
Q2 2024 Aug 09, 2024	BUY	$37.42 - $51.61 $275,635 - $380,159	7,366 Added 4.74%	162,891 $6.69 Million
Q1 2024 May 09, 2024	BUY	$43.02 - $53.69 $2.97 Million - $3.71 Million	69,068 Added 79.89%	155,525 $7.26 Million
Q4 2023 Feb 09, 2024	SELL	$31.73 - $49.19 $3.04 Million - $4.71 Million	-95,778 Reduced 52.56%	86,457 $4.13 Million
Q3 2023 Nov 13, 2023	SELL	$34.92 - $46.66 $830,956 - $1.11 Million	-23,796 Reduced 11.55%	182,235 $6.5 Million
Q2 2023 Aug 10, 2023	SELL	$37.35 - $52.15 $68,238 - $95,278	-1,827 Reduced 0.88%	206,031 $9.5 Million
Q1 2023 May 09, 2023	SELL	$36.99 - $48.71 $826,208 - $1.09 Million	-22,336 Reduced 9.7%	207,858 $8.34 Million
Q4 2022 Feb 10, 2023	BUY	$33.72 - $46.33 $1.41 Million - $1.94 Million	41,773 Added 22.17%	230,194 $10.7 Million
Q3 2022 Nov 10, 2022	BUY	$39.96 - $66.14 $6.23 Million - $10.3 Million	155,840 Added 478.32%	188,421 $7.8 Million
Q2 2022 Aug 05, 2022	BUY	$45.8 - $85.4 $1.49 Million - $2.78 Million	32,581 New	32,581 $1.94 Million
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $183,657 - $241,356	-2,357 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$92.19 - $115.71 $1.21 Million - $1.52 Million	-13,109 Reduced 84.76%	2,357 $225,000
Q1 2021 May 13, 2021	BUY	$106.9 - $167.73 $1.37 Million - $2.15 Million	12,840 Added 488.96%	15,466 $1.76 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $221,634 - $465,826	2,626 New	2,626 $364,000

Others Institutions Holding RARE

# of Institutions

362

Shares Held

88.3M

Call Options Held

3.64M

Put Options Held

2.24M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.41B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Ultragenyx Pharmaceutical Inc. Transaction History